as of 12-05-2025 2:46pm EST
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 99.1M | IPO Year: | 2014 |
| Target Price: | $21.00 | AVG Volume (30 days): | 63.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.00 - $18.70 | Next Earning Date: | 11-12-2025 |
| Revenue: | $151,930,000 | Revenue Growth: | 51.27% |
| Revenue Growth (this year): | -4.19% | Revenue Growth (next year): | -52.16% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
President and CEO
Avg Cost/Share
$13.19
Shares
2,915
Total Value
$38,437.30
Owned After
65,030
Chief Accounting Officer
Avg Cost/Share
$13.19
Shares
1,804
Total Value
$23,788.08
Owned After
33,613
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Nguyen AnhCo | ATRA | President and CEO | Nov 17, 2025 | Sell | $13.19 | 2,915 | $38,437.30 | 65,030 | |
| Grant-Huerta Yanina | ATRA | Chief Accounting Officer | Nov 17, 2025 | Sell | $13.19 | 1,804 | $23,788.08 | 33,613 |
See how ATRA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ATRA Atara Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.